Novo Nordisk A/S (NYSE:NVO) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD trimmed its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 33.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,345,118 shares of the company's stock after selling 3,238,317 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.14% of Novo Nordisk A/S worth $545,809,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in NVO. Victory Capital Management Inc. lifted its stake in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares during the last quarter. Norman Fields Gottscho Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock valued at $5,482,000 after acquiring an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after acquiring an additional 30,420 shares in the last quarter. Versant Capital Management Inc acquired a new position in shares of Novo Nordisk A/S in the 4th quarter worth $86,000. Finally, Talbot Financial LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $4,066,000. Institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NVO shares. BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus target price of $135.00.

Novo Nordisk A/S Trading Up 2.1 %

NYSE NVO opened at $62.59 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The firm's fifty day simple moving average is $74.03 and its 200-day simple moving average is $90.18. The company has a market capitalization of $280.87 billion, a PE ratio of 19.02, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were given a $0.7874 dividend. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S's payout ratio is currently 49.54%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.